Translations:Research/key-initiatives/ras/spokes-funding/13/en
Jump to navigation
Jump to search
| William Hahn, Broad Institute, for "Systematic Identification of Oncogenic KRAS Synthetic Lethal Interactions." Dr. Hahn and his team will perform genome scale CRISPR mediated loss of function experiments to identify KRAS co-dependencies in both in vitro and in vivo model systems and identify genes and pathways that when inhibited synergize with known KRAS effector pathways to induce tumor regression in KRAS driven cancers. Targets identified by these approaches will form the basis of translational studies to develop novel therapeutic approaches. |
